{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:16:47Z","timestamp":1791231407618,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Type 2 inflammatory diseases (T2D), notably severe eosinophilic asthma (SEA) and chronic rhinosinusitis with nasal polyps (CRSwNP), represent a significant global health burden due to their high morbidity, frequent exacerbations and reliance on systemic glucocorticoids (SGCs). Targeting Interleukin-5 (IL-5), a key driver of eosinophil production and survival, has emerged as a validated therapeutic strategy. Depemokimab is a novel, first-in-class anti-IL-5 monoclonal antibody (mAb) engineered with an extended half-life via the YTE amino acid modification of its Fc region, enabling an unprecedented twice-yearly dosing interval. This review synthesizes clinical data from the Phase III SWIFT (SEA) and ANCHOR (CRSwNP) programs, demonstrating depemokimab\u2019s sustained eosinophil depletion and significant reduction in asthma exacerbation rates (annualized asthma exacerbation rate reduction of approximately 54% versus placebo). While efficacy on secondary endpoints such as lung function (FEV1) and quality of life (QoL) was mixed, the efficacy in reducing nasal polyp size (Nasal Polyp Score and Nasal Congestion) in CRSwNP was clear. The core value proposition of depemokimab is the combination of established IL-5 inhibition efficacy with patient convenience due to its dosing. We discuss its pharmacodynamic profile, safety and pivotal role in shifting the treatment paradigm towards simplified chronic disease management, positioning depemokimab as a novel, patient-centric option in the competitive landscape of T2 biologic therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1783889","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:58:13Z","timestamp":1773817093000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"A. M.","family":"Marra","sequence":"first","affiliation":[{"name":"Pulmonology Unit, Azienda Socio-Sanitaria Territoriale (ASST) Rhodense, Garbagnate Milanese Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bizzi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gidaro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sacco Hospital, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli and Sacco Hospitals","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bini","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, Azienda Socio-Sanitaria Territoriale (ASST) Rhodense, Garbagnate Milanese Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rotunno","sequence":"additional","affiliation":[{"name":"Internal Medicine, S.Pietro Fatebenefratelli Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Modica","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergology and Clinical Immunology, Department of \u201cMedicina dei Sistemi\u201d, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Greco","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergology and Clinical Immunology, Department of \u201cMedicina dei Sistemi\u201d, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Fatebenefratelli Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mascolo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fatebenefratelli Hospital, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli and Sacco Hospitals","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tombetti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fatebenefratelli Hospital, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli and Sacco Hospitals","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lazzeroni","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology & Head and Neck Surgery, Fatebenefratelli Hospital, ASST Fatebenefratelli Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Paciullo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Abatianni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gagliardi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Damanti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rovere Querini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/life14070899","article-title":"Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model","volume":"14","author":"Ambrosino","year":"2024","journal-title":"Life (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.06.047","article-title":"Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision","volume":"126","author":"Brozek","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-017-0065-4","article-title":"SANI. SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma","volume":"15","author":"Senna","year":"2017","journal-title":". Clin Mol Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.03.001","article-title":"Clinical Remission in Severe Asthma: How to Move From Theory to Practice","volume":"164","author":"Menzies-Gow","year":"2023","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin24.457","article-title":"Remission in chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"63","author":"Hellings","year":"2025","journal-title":"Rhinology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.10.022","article-title":"Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma","volume":"5","author":"Nolasco","year":"2024","journal-title":"Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1506","article-title":"Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single-Dose Study","volume":"14","author":"Schalkwijk","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/17476348.2025.2545571","article-title":"Mepolizumab for severe eosinophilic asthma","volume":"20","author":"Kallieri","year":"2026","journal-title":"Expert Rev Respir Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70083","article-title":"Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction","volume":"55","author":"Louis","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S558065","article-title":"Targeting the IL-4\/IL-4R Axis in Th2 Inflammatory Diseases: A Review of Clinical Efficacy and Safety","volume":"18","author":"Li","year":"2025","journal-title":"J Inflammation Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ajrccm\/aamag031","article-title":"NIMBLE Study Investigators. Switching to twice-yearly depemokimab from mepolizumab\/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)","volume":"11","author":"Chupp","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S365117","article-title":"Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study","author":"Yang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.10.050","article-title":"Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes","volume":"159","author":"Maddux","year":"2021","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.09.020","article-title":"Real-World Adherence to Biologic Therapy for Severe Asthma in Children","volume":"13","author":"Rose","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","unstructured":""},{"key":"B30","first-page":"19","article-title":"Major cost savings associated with biologic dose reduction in patients with inflammatory arthritis","volume":"108","author":"Murphy","year":"2015","journal-title":"Ir Med J"},{"key":"B31","unstructured":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)"},{"key":"B32","unstructured":"Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:58:16Z","timestamp":1773817096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1783889"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1783889","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1783889"}}